Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, CDER provides scientific and regulatory advice needed to bring new therapies to market.
The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. For this reason, CDER supports innovation and plays a key role in helping to advance new drug development.
Each year, CDER approves a wide range of new drugs and biological products:
Some of these products are innovative new products that never have been used in clinical practice. Below is a listing of new molecular entities and new therapeutic biological products approved by CDER in 2020. This listing does not contain vaccines, allergenic products, blood and blood products, plasma derivatives, cellular and gene therapy products, or other products approved in 2020 by the Center for Biologics Evaluation and Research. Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace. See Drugs@FDA for information about all of CDER’s approved drugs and biological products.
Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that have previously been approved by FDA. For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act.
No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date* |
---|---|---|---|---|
11 | Azstarys | serdexmethylphenidate and dexmethylphenidate |
3/3/2021 | For the treatment of Attention Deficit Hyperactivity |
10. | Pepaxto | melphalan flufenamide | 2/26/2021 | For the treatment of certain patients with relapsed or refractory multiple myeloma |
9. | Nulibry | fosdenopterin | 2/26/2021 | To treat patients with the rare genetic disease molybdenum cofactor deficiency Type A Press Release |
8. | Amondys 45 | casimersen | 2/25/2021 | For the treatment of Duchenne muscular dystrophy Press Release |
7. | Cosela | trilacicilib | 2/12/2021 | To mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer Press Release |
6. | Evkeeza | evinacumab-dgnb | 2/11/2021 | For the treatment of homozygous familial hypercholesterolemia |
5. | Ukoniq | umbralisib | 2/5/2021 | For the treatment of certain patients with marginal zone lymphoma and follicular lymphoma |
4. | Tepmetko | tepotinib | 2/3/2021 | To treat non-small cell lung cancer |
3. | Lupkynis | voclosporin | 1/22/2021 | To treat lupus nephritis Drug Trials Snapshot |
2. | Cabenuva | cabotegravir and rilpivirine | 1/21/2021 | To treat HIV Press Release Drug Trials Snapshot |
1. | Verquvo | vericiguat | 1/19/2021 | To treat chronic heart failure Drug Trials Snapshot |
New Drugs 2020
No. |
Drug Name | Active Ingredient | Approval | FDA-approved use on approval date* | Expandable |
Date | Label | ||||
42 | Veklury | remdesivir | 10/22/2020 | To treat COVID-19 | Label |
Press Release | |||||
41 | Inmazeb | atoltivimab, maftivimab, and odesivimab-ebgn | 10/14/2020 | To treat ebola virus | Label |
Press Release | |||||
40 | Gavreto | pralsetinib | 9/4/2020 | To treat non-small lung cancer | Label |
Drug Trials Snapshot | |||||
39 | Detectnet | copper Cu 64 dotatate injection | 9/3/2020 | To help detect certain types of neuroendocrine tumors | Label |
Drug Trials Snapshot | |||||
38 | Sogroya | somapacitan-beco | 8/28/2020 | Growth hormone | Label |
Drug Trials Snapshot | |||||
37 | Winlevi | clascoterone | 8/26/2020 | To treat acne | Label |
Drug Trials Snapshot | |||||
36 | Enspryng | satralizumab-mwge | 8/14/2020 | To treat neuromyelitis optica spectrum disorder | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
35 | Viltepso | viltolarsen | 8/12/2020 | To treat Duchenne muscular dystrophy | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
34 | Olinvyk | oliceridine | 8/7/2020 | To manage acute pain in certain adults | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
33 | Evrysdi | risdiplam | 8/7/2020 | To treat spinal muscular atrophy | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
32 | Lampit | nifurtimox | 8/6/2020 | To treat Chagas disease in certain pediatric patients younger than age 18 | Label |
Drug Trials Snapshot | |||||
31 | Blenrep | belantamab mafodotin-blmf) | 8/5/2020 | To treat multiple myeloma | Label |
Drug Trials Snapshot | |||||
30 | Monjuvi | tafasitamab-cxix | 7/31/2020 | To treat relapsed or refractory diffuse large B-cell lymphoma | Label |
Drug Trials Snapshot | |||||
29 | Xeglyze | abametapir | 7/24/2020 | To treat head lice | Label |
Drug Trials Snapshot | |||||
28 | Inqovi | decitabine and cedazuridine | 7/7/2020 | To treat adult patients with myelodysplastic syndromes | Label |
Drug Trials Snapshot | |||||
27 | Rukobia | fostemsavir | 7/2/2020 | To treat HIV | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
26 | Byfavo | remimazolam | 7/2/2020 | For sedation | Label |
Drug Trials Snapshot | |||||
25 | Dojolvi | triheptanoin | 6/30/2020 | To treat molecularly long-chain fatty acid oxidation disorders | Label |
Drug Trials Snapshot | |||||
24 | Zepzelca | lurbinectedin | 6/15/2020 | To treat metastatic small cell lung cancer | Label |
Drug Trials Snapshot | |||||
23 | Uplizna | inebilizumab-cdon | 6/11/2020 | To treat neuromyelitis optica spectrum disorder | Label |
Press Release | |||||
22 | Tauvid | flortaucipir F18 | 5/28/2020 | Diagnostic agent for patients with Alzheimer’s disease | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
21 | Artesunate | artesunate | 5/26/2020 | To treat severe malaria | Label |
Press Release | |||||
20 | Cerianna | fluoroestrdiol F18 | 5/20/2020 | Diagnostic imaging agent for certain patients with breast cancer | Label |
Drug Trials Snapshot | |||||
19 | Qinlock | ripretinib | 5/15/2020 | To treat advanced gastrointestinal-stromal tumors | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
18 | Retevmo | selpercatinib | 5/8/2020 | To treat lung and thyroid cancers | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
17 | Tabrecta | capmatinib | 5/6/2020 | To treat patients with non small cell lung cancer | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
16 | Ongentys | opicapone | 4/24/2020 | To treat patients with Parkinson’s disease experiencing “off” episodes | Label |
Drug Trials Snapshot | |||||
15 | Trodelvy | sacituzumab govitecan-hziy | 4/22/2020 | To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
14 | Pemazyre | pemigatinib | 4/17/2020 | To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
13 | Tukysa | tucatinib | 4/17/2020 | To treat advanced unresectable or metastatic HER2-positive breast cancer | Label |
Drug Trials Snapshot | |||||
12 | Koselugo | selumetinib | 4/10/2020 | To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves | Label |
Drug Trials Snapshot | |||||
11 | Zeposia | ozanimod | 3/25/2020 | To treat relapsing forms of multiple sclerosis | Label |
10 | Isturisa | osilodrostat | 3/6/2020 | To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
9 | Sarclisa | isatuximab | 3/2/2020 | To treat multiple myloma | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
8 | Nurtec ODT | rimegepant | 2/27/2020 | To treat migraine | Label |
Drug Trials Snapshot | |||||
7 | Barhemsys | amisulpride | 2/26/2020 | To help prevent nausea and vomiting after surgery | Label |
Drug Trial Snapshot | |||||
6 | Vyepti | eptinezumab-jjmr | 2/21/2020 | For the preventive treatment of migraine in adults | Label |
Drug Trials Snapshot | |||||
5 | Nexletol | bempedoic acid | 2/21/2020 | To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C | Label |
Drug Trials Snapshot | |||||
4 | Pizensy | lactitol | 2/12/2020 | To treat chronic idiopathic constipation (CIC) in adults | Label |
Drug Trials Snapshot | |||||
3 | Tazverik | tazemetostat | 1/23/2020 | To treat epithelioid sarcoma | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
2 | Tepezza | teprotumumab-trbw | 1/21/2020 | To treat Thyroid eye disease | Label |
Press Release | |||||
Drug Trials Snapshot | |||||
1 | Ayvakit | avapritinib | 1/9/2020 | To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) | Label |
FDA Information | |||||
Drug Trials Snapshot |
New Hampshire Pharmacists Association 373 South Willow Street D1-1, Suite 165 Manchester, NH 03103 Email: info@nhpharmacists.net | NHPA Mission Statement The mission of the New Hampshire Pharmacists Association is to promote, enhance, and advance pharmacy practice, in the State of New Hampshire by advocating for the professional interests of pharmacists, pharmacy technicians, student pharmacists, and ancillary pharmacy personnel as well as to advocate for the health and welfare of the general public. | You will only receive notification about our CE Programs, Dinner Social Events, and legislative alerts. Our list is never shared or sold for any reason. |
Your NHPA website has been updated and is now smartphone friendly.
Please take the time to view the website from your laptop as well as from your smartphone.
We look forward to your comments and suggestions.